Machina Capital S.A.S. Buys New Holdings in Natera, Inc. $NTRA

Machina Capital S.A.S. acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,143 shares of the medical research company’s stock, valued at approximately $362,000.

Several other large investors have also recently made changes to their positions in the company. Mission Wealth Management LP acquired a new position in shares of Natera in the 2nd quarter valued at $228,000. Zweig DiMenna Associates LLC lifted its stake in shares of Natera by 3.0% in the 2nd quarter. Zweig DiMenna Associates LLC now owns 124,100 shares of the medical research company’s stock valued at $20,965,000 after purchasing an additional 3,610 shares during the period. Earned Wealth Advisors LLC lifted its stake in shares of Natera by 7.3% in the 2nd quarter. Earned Wealth Advisors LLC now owns 1,864 shares of the medical research company’s stock valued at $315,000 after purchasing an additional 127 shares during the period. Simon Quick Advisors LLC lifted its stake in shares of Natera by 27.7% in the 2nd quarter. Simon Quick Advisors LLC now owns 2,045 shares of the medical research company’s stock valued at $345,000 after purchasing an additional 444 shares during the period. Finally, Strs Ohio lifted its position in shares of Natera by 4.2% during the 2nd quarter. Strs Ohio now owns 66,261 shares of the medical research company’s stock valued at $11,194,000 after buying an additional 2,671 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 2,491 shares of Natera stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total transaction of $403,666.55. Following the transaction, the chief financial officer owned 69,189 shares in the company, valued at $11,212,077.45. The trade was a 3.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of Natera stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the transaction, the chief executive officer owned 144,816 shares in the company, valued at approximately $28,957,407.36. This represents a 52.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 224,889 shares of company stock worth $43,232,062 in the last quarter. 5.63% of the stock is currently owned by insiders.

Natera Stock Down 0.9%

Natera stock opened at $196.45 on Wednesday. Natera, Inc. has a 52-week low of $122.08 and a 52-week high of $203.23. The firm has a market capitalization of $26.96 billion, a price-to-earnings ratio of -102.85 and a beta of 1.75. The company has a fifty day simple moving average of $175.77 and a 200-day simple moving average of $162.77.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same period in the previous year, the company earned ($0.30) EPS. Natera’s quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on NTRA shares. Canaccord Genuity Group reiterated a “buy” rating and set a $200.00 target price on shares of Natera in a research report on Tuesday, October 14th. Cowen reiterated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Piper Sandler reiterated an “overweight” rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Finally, BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 price objective on the stock in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $194.89.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.